Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives $27.80 Average Price Target from Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $27.80.

A number of equities research analysts recently issued reports on the company. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Truist Financial increased their target price on Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Monday, May 12th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 34.0% during the first quarter. GAMMA Investing LLC now owns 9,603 shares of the company’s stock valued at $239,000 after buying an additional 2,439 shares during the last quarter. Cerity Partners LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 22.4% in the first quarter. Cerity Partners LLC now owns 39,903 shares of the company’s stock worth $994,000 after purchasing an additional 7,299 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $447,000. Point72 Asset Management L.P. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $850,000. Finally, Forum Financial Management LP bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $247,000. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.2%

Fresenius Medical Care AG & Co. KGaA stock opened at $25.5750 on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.94 and a 12 month high of $30.46. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. The business’s 50 day simple moving average is $26.41 and its 200 day simple moving average is $25.80.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The firm had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $5 billion. As a group, research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.